Amgen Inc. Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain (Loss), Net
Amgen Inc. (AMGN) reported Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain (Loss), Net of $80.00 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-07-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainOrLoss · last filed 2018-07-27
- Amgen Inc. business combination, step acquisition, equity interest in acquiree, remeasurement gain (loss), net for the quarter ending 2018-03-31 was $80.00M.
| Period end | Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain (Loss), Net 3 month |
|---|---|
| 2018-03-31 | $80.00M 10-Q · filed 2018-07-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |